|
Florida CMO Flagged by FDA for Unjustified Process Deviations
Axara Pharmaceuticals has not justified deviations from process control procedures that resulted in drug products gone astray and equipment cleaning confusion, according to an FDA Form 483.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives